These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 3440867)
1. Muscarinic cholinergic receptor subtypes in normal human brain and Alzheimer's presenile dementia. Vanderheyden P; Ebinger G; Dierckx R; Vauquelin G J Neurol Sci; 1987 Dec; 82(1-3):257-69. PubMed ID: 3440867 [TBL] [Abstract][Full Text] [Related]
2. Different agonist binding properties of M1 and M2 muscarinic receptors in calf brain cortex membranes. Vanderheyden P; Ebinger G; Vauquelin G Biochem Pharmacol; 1987 Dec; 36(23):4119-24. PubMed ID: 3689439 [TBL] [Abstract][Full Text] [Related]
3. Muscarinic cholinergic receptor subtypes in the human brain. II. Quantitative autoradiographic studies. Cortés R; Probst A; Tobler HJ; Palacios JM Brain Res; 1986 Jan; 362(2):239-53. PubMed ID: 3753655 [TBL] [Abstract][Full Text] [Related]
4. Gallamine binding to muscarinic M1 and M2 receptors, studied by inhibition of [3H]pirenzepine and [3H]quinuclidinylbenzilate binding to rat brain membranes. Burke RE Mol Pharmacol; 1986 Jul; 30(1):58-68. PubMed ID: 3755217 [TBL] [Abstract][Full Text] [Related]
5. Characterization of M1- and M2-muscarinic receptors in calf retina membranes. Vanderheyden P; Ebinger G; Vauquelin G Vision Res; 1988; 28(2):247-50. PubMed ID: 3414010 [TBL] [Abstract][Full Text] [Related]
6. Identification of M2 muscarinic receptors in membranes from bovine cerebral basal arteries. Vanderheyden P; Ebinger G; De Backer JP; Vauquelin G Life Sci; 1986 Oct; 39(17):1517-23. PubMed ID: 3762314 [TBL] [Abstract][Full Text] [Related]
7. Regional distribution of M1, M2 and non-M1, non-M2 subtypes of muscarinic binding sites in rat brain. Ehlert FJ; Tran LP J Pharmacol Exp Ther; 1990 Dec; 255(3):1148-57. PubMed ID: 2262898 [TBL] [Abstract][Full Text] [Related]
8. Cholinergic innervation and topographical organization of muscarinic binding sites in rat brain: a comparative autoradiographic study. Tonnaer JA; Ernste BH; Wester J; Kelder K J Chem Neuroanat; 1988; 1(2):95-110. PubMed ID: 3267343 [TBL] [Abstract][Full Text] [Related]
9. Human M1-, M2- and M3-muscarinic cholinergic receptors: binding characteristics of agonists and antagonists. Vanderheyden P; Gies JP; Ebinger G; De Keyser J; Landry Y; Vauquelin G J Neurol Sci; 1990 Jun; 97(1):67-80. PubMed ID: 2370560 [TBL] [Abstract][Full Text] [Related]
10. Selectivity of oxomemazine for the M1 muscarinic receptors. Lee SW; Woo CW; Kim JG Arch Pharm Res; 1994 Dec; 17(6):443-51. PubMed ID: 10319156 [TBL] [Abstract][Full Text] [Related]
11. Differential alteration of various cholinergic markers in cortical and subcortical regions of human brain in Alzheimer's disease. Araujo DM; Lapchak PA; Robitaille Y; Gauthier S; Quirion R J Neurochem; 1988 Jun; 50(6):1914-23. PubMed ID: 3373218 [TBL] [Abstract][Full Text] [Related]
12. Loss of high-affinity agonist binding to M1 muscarinic receptors in Alzheimer's disease: implications for the failure of cholinergic replacement therapies. Flynn DD; Weinstein DA; Mash DC Ann Neurol; 1991 Mar; 29(3):256-62. PubMed ID: 2042942 [TBL] [Abstract][Full Text] [Related]
13. Regional alterations in M1 muscarinic receptor-G protein coupling in Alzheimer's disease. Ladner CJ; Celesia GG; Magnuson DJ; Lee JM J Neuropathol Exp Neurol; 1995 Nov; 54(6):783-9. PubMed ID: 7595651 [TBL] [Abstract][Full Text] [Related]
14. A unique regulatory profile and regional distribution of [3H]pirenzepine binding in the rat provide evidence for distinct M1 and M2 muscarinic receptor subtypes. Watson M; Yamamura HI; Roeske WR Life Sci; 1983 Jun; 32(26):3001-11. PubMed ID: 6688111 [TBL] [Abstract][Full Text] [Related]
15. Muscarinic cholinergic receptor subtypes in the rat brain. I. Quantitative autoradiographic studies. Cortés R; Palacios JM Brain Res; 1986 Jan; 362(2):227-38. PubMed ID: 3942874 [TBL] [Abstract][Full Text] [Related]
16. Muscarinic receptors in canine colonic circular smooth muscle. I. Coexistence of M2 and M3 subtypes. Zhang LB; Horowitz B; Buxton IL Mol Pharmacol; 1991 Dec; 40(6):943-51. PubMed ID: 1758444 [TBL] [Abstract][Full Text] [Related]
17. [3H]pirenzepine and (-)-[3H]quinuclidinyl benzilate binding to rat cerebral cortical and cardiac muscarinic cholinergic sites. II. Characterization and regulation of antagonist binding to putative muscarinic subtypes. Watson M; Roeske WR; Yamamura HI J Pharmacol Exp Ther; 1986 May; 237(2):419-27. PubMed ID: 3754581 [TBL] [Abstract][Full Text] [Related]
18. Effects of in vivo and in vitro treatments with N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline on putative muscarinic receptor subtypes in rat brain. Norman AB; Creese I Mol Pharmacol; 1986 Aug; 30(2):96-103. PubMed ID: 3755499 [TBL] [Abstract][Full Text] [Related]
19. Comparative distribution of binding of the muscarinic receptor ligands pirenzepine, AF-DX 384, (R,R)-I-QNB and (R,S)-I-QNB to human brain. Piggott M; Owens J; O'Brien J; Paling S; Wyper D; Fenwick J; Johnson M; Perry R; Perry E J Chem Neuroanat; 2002 Sep; 24(3):211-23. PubMed ID: 12297267 [TBL] [Abstract][Full Text] [Related]
20. Distinct kinetic binding properties of N-[3H]-methylscopolamine afford differential labeling and localization of M1, M2, and M3 muscarinic receptor subtypes in primate brain. Flynn DD; Mash DC Synapse; 1993 Aug; 14(4):283-96. PubMed ID: 8248852 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]